Business
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress
MONMOUTH JUNCTION, N.J., April 28, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J., April 28, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company will participate in the 10th EuroELSO Congress (EuroELSO 2022) in London, UK being held May 4-6, 2022, one of the two major conferences for ECMO (extracorporeal membrane oxygenation) users worldwide. CytoSorbents is highlighting the strategy of \"enhanced lung rest\" using CytoSorb with ECMO to help treat acute respiratory distress syndrome (ARDS) and lung failure – both major causes of death in ICU patients.\n\n \n \n \n \n \n \n\n \nCytoSorbents Highlights \"Enhanced Lung Rest\" Strategy Using CytoSorb + ECMO to Help Treat Lung Failure at EuroELSO 2022New clinical data from 56 critically ill COVID-19 patients with refractory respiratory failure on life support with ECMO and treated with CytoSorb under FDA Emergency Use Authorization (EUA) from the U.S. CTC Registry will be presented on Thursday, May 5, 2022, in an abstract presentation titled: ECMO Utilization with Adjunctive Hemoadsorption Therapy in COVID-19 Patients: An Observational Analysis from the CytoSorb Therapy in COVID-19 (CTC) Registry. This new analysis supports the importance of early intervention with CytoSorb and ECMO in treating patients with COVID-related ARDS, and its potential role in the high observed survival of 52 patients in an earlier analysis of the registry, published in the peer-reviewed journal, Frontiers in Medicine, last year. \nCytoSorbents is a platinum sponsor of the Congress and will also host an onsite educational symposium which will be livestreamed on the EuroELSO website, entitled \"ECMO plus CytoSorb – Are We Doing It Right?\" on Thursday, May 5, 2022, from 12:45-1:45 PM CET in the St. James room (see detail below).\nChairsProf. Roberto Lorusso (Deputy Director, Department of Cardio-Thoracic Surgery Heart and Vascular Centre, Maastricht University Medical Centre, The Netherlands) and Prof. Federico Pappalardo (Director of Cardiothoracic and Vascular Anesthesia and Intensive Care, National Hospital Allesandria, Italy)\nSpeakersDr. J.W. Awori Hayanga (Professor of Cardiovascular and Thoracic Surgery and ECMO Program Director at the Heart and Vascular Institute, West Virginia University Scho...